Meitheal Patent-Cliff Exposure & CMS Drug Spending Portfolio

Meitheal (US): 5 reconciled FDA prescription therapies, $118K 2024 CMS Part D & Medicaid spend, and $2,193 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies5
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2039-01-01
2024 CMS Total Public Spend$118K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$118K
California HCAI SB 17 FilingsSpecialty launch notice ($2,193 intro WAC)